Skip to main content
main-content
Erschienen in: Neurological Sciences 10/2022

03.08.2022 | COVID-19 | COVID-19

Hypogammaglobulinemia is associated with reduced antibody response after anti-SARS-CoV-2 vaccination in MS patients treated with antiCD20 therapies

verfasst von: Angelo Bellinvia, Maria Grazia Aprea, Emilio Portaccio, Luisa Pastò, Lorenzo Razzolini, Mattia Fonderico, Ilaria Addazio, Matteo Betti, Maria Pia Amato

Erschienen in: Neurological Sciences | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

COVID-19 vaccination is highly recommended to multiple sclerosis (MS) patients. Little is known about the role of patients’ clinical and demographic characteristics in determining antibody response.

Methods

We evaluated safety and efficacy of anti-SARS-CoV-2 vaccines on 143 included MS patients. Then, we analyzed antibody titer in a subgroup, assessing clinical and demographic variables associated with protection and antibody titer.

Results

After completing the vaccination cycle, the rate of local adverse events was similar after the first and second dose. A higher proportion of systemic AEs was reported after the second dose (65.7% vs 24.5% after the first dose). Antibody response was evaluated in 97 patients. Higher EDSS (OR 0.6, 95% CI 0.4–0.9, p = 0.006) and treatment with antiCD20 (OR 0.02, 95% CI 0.003–0.098, p 0.001) were associated with a lower chance of having an efficacious response. Higher weight was associated with higher Ab titer (β = 15.2, 95% CI 2.8–27.6, p = 0.017), while treatment with antiCD20 with lower titers (β =  − 1092.3, 95% CI − 1477.4 to − 702.2, p < 0.001). In patients treated with antiCD20, hypogammaglobulinemia (β − 543, 95% CI − 1047.6 to − 39.1, p = 0.036) and treatment duration (β − 182, 95% CI − 341.4 to − 24.3, p = 0.027) were associated with lower Ab titer.

Conclusion

Our study confirms that COVID-19 vaccination in MS patient is safe and effective in preventing symptomatic COVID-19 and should be recommended to all patients. Moreover, we suggest a possible role of hypogammaglobulinemia in reducing Ab response in patients treated with antiCD20 therapies.
Literatur
1.
Zurück zum Zitat Hodgson SH et al (2021) What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis 21:e26–e35 CrossRef Hodgson SH et al (2021) What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis 21:e26–e35 CrossRef
2.
Zurück zum Zitat Centonze D et al (2021) Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. J Neurol 268:3961–3968 CrossRef Centonze D et al (2021) Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. J Neurol 268:3961–3968 CrossRef
3.
Zurück zum Zitat Achiron A et al (2021) COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021. Mult Scler 27:864–870 CrossRef Achiron A et al (2021) COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021. Mult Scler 27:864–870 CrossRef
10.
Zurück zum Zitat Conte WL (2022) B-cell depleters attenuate the humoral response to SARS-CoV-2 vaccines in multiple sclerosis patients: a case-control study. Mult Scler Relat Dis 57:103413 CrossRef Conte WL (2022) B-cell depleters attenuate the humoral response to SARS-CoV-2 vaccines in multiple sclerosis patients: a case-control study. Mult Scler Relat Dis 57:103413 CrossRef
11.
Zurück zum Zitat Katz JD et al (2022) Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab. Mult Scler Relat Disord 57:103382 CrossRef Katz JD et al (2022) Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab. Mult Scler Relat Disord 57:103382 CrossRef
12.
Zurück zum Zitat Brill L et al (2022) Effect of cladribine on COVID-19 serology responses following two doses of the BNT162b2 mRNA vaccine in patients with multiple sclerosis. Mult Scler Relat Dis 57:103343 CrossRef Brill L et al (2022) Effect of cladribine on COVID-19 serology responses following two doses of the BNT162b2 mRNA vaccine in patients with multiple sclerosis. Mult Scler Relat Dis 57:103343 CrossRef
13.
Zurück zum Zitat Brill L et al (2021) Humoral and T-cell response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab. JAMA Neurol 78:1510–1514 CrossRef Brill L et al (2021) Humoral and T-cell response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab. JAMA Neurol 78:1510–1514 CrossRef
16.
Zurück zum Zitat Achiron A et al (2021) Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord 14:17562864211012836 Achiron A et al (2021) Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord 14:17562864211012836
17.
Zurück zum Zitat Apostolidis SA et al (2021) Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med 27(11):1990–2001 CrossRef Apostolidis SA et al (2021) Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med 27(11):1990–2001 CrossRef
20.
Zurück zum Zitat Achiron A et al (2022) Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod. J Neurol 1:1 Achiron A et al (2022) Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod. J Neurol 1:1
22.
Zurück zum Zitat Tallantyre EC et al (2022) COVID-19 vaccine response in people with multiple sclerosis. Ann Neurol 91:89–100 CrossRef Tallantyre EC et al (2022) COVID-19 vaccine response in people with multiple sclerosis. Ann Neurol 91:89–100 CrossRef
23.
Zurück zum Zitat Baker D et al (2020) COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol 202:149–161 CrossRef Baker D et al (2020) COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol 202:149–161 CrossRef
24.
Zurück zum Zitat Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1444 CrossRef Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1444 CrossRef
25.
Zurück zum Zitat Pharmacovigilance V (2005) Definition and application of terms for vaccine pharmacovigilance this report from the Council for International Organizations of Medical Sciences (CIOMS) in collaboration with WHO covers the activities and outputs of the CIOMS/WHO Working Group on Pharmacovigilance V (2005) Definition and application of terms for vaccine pharmacovigilance this report from the Council for International Organizations of Medical Sciences (CIOMS) in collaboration with WHO covers the activities and outputs of the CIOMS/WHO Working Group on
27.
Zurück zum Zitat WHO International Standard First WHO International Standard for anti-SARS-CoV-2 immunoglobulin (human) NIBSC code: 20/136 Instructions for use (Version 2.0, Dated 17/12/2020). https://​doi.​org/​10.​1016/​S0140-6736(21)00527-4. Epub 2021 Mar 23 WHO International Standard First WHO International Standard for anti-SARS-CoV-2 immunoglobulin (human) NIBSC code: 20/136 Instructions for use (Version 2.0, Dated 17/12/2020). https://​doi.​org/​10.​1016/​S0140-6736(21)00527-4. Epub 2021 Mar 23
28.
Zurück zum Zitat Baden LR et al (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384:403–416 CrossRef Baden LR et al (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384:403–416 CrossRef
29.
Zurück zum Zitat Polack FP et al (2020) Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 383:2603–2615 CrossRef Polack FP et al (2020) Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 383:2603–2615 CrossRef
32.
Zurück zum Zitat Watanabe M et al (2022) Rapid weight loss, central obesity improvement and blood glucose reduction are associated with a stronger adaptive immune response following COVID-19 mRNA vaccine. Vaccines 10:79 CrossRef Watanabe M et al (2022) Rapid weight loss, central obesity improvement and blood glucose reduction are associated with a stronger adaptive immune response following COVID-19 mRNA vaccine. Vaccines 10:79 CrossRef
34.
Zurück zum Zitat Bigaut K et al (2021) Impact of disease-modifying treatments on humoral response after COVID-19 vaccination: a mirror of the response after SARS-CoV-2 infection. Rev Neurol (Paris) 177:1237–1240 CrossRef Bigaut K et al (2021) Impact of disease-modifying treatments on humoral response after COVID-19 vaccination: a mirror of the response after SARS-CoV-2 infection. Rev Neurol (Paris) 177:1237–1240 CrossRef
36.
Zurück zum Zitat Tešija Kuna A et al (2021) Comparison of diagnostic accuracy for eight SARS-CoV-2 serological assays. Biochemia Medica 31:1–13 Tešija Kuna A et al (2021) Comparison of diagnostic accuracy for eight SARS-CoV-2 serological assays. Biochemia Medica 31:1–13
37.
38.
Zurück zum Zitat Kontou PI, Braliou GG, Dimou NL, Nikolopoulos G, Bagos PG (2020) Antibody tests in detecting SARS-CoV-2 infection: a meta-analysis. Diagnostics (Basel) 10(5):319. http://​doi.​org/​10.​3390/​diagnostics10050​319 Kontou PI, Braliou GG, Dimou NL, Nikolopoulos G, Bagos PG (2020) Antibody tests in detecting SARS-CoV-2 infection: a meta-analysis. Diagnostics (Basel) 10(5):319. http://​doi.​org/​10.​3390/​diagnostics10050​319
Metadaten
Titel
Hypogammaglobulinemia is associated with reduced antibody response after anti-SARS-CoV-2 vaccination in MS patients treated with antiCD20 therapies
verfasst von
Angelo Bellinvia
Maria Grazia Aprea
Emilio Portaccio
Luisa Pastò
Lorenzo Razzolini
Mattia Fonderico
Ilaria Addazio
Matteo Betti
Maria Pia Amato
Publikationsdatum
03.08.2022
Verlag
Springer International Publishing
Schlagwort
COVID-19
Erschienen in
Neurological Sciences / Ausgabe 10/2022
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-022-06287-2